logo
Popular lemonade recalled due to undeclared ingredient linked to cancer

Popular lemonade recalled due to undeclared ingredient linked to cancer

Yahoo28-02-2025

A popular lemonade recall has received an update, as the drink contains a food additive linked to an increased cancer risk.
On January 31, Oak Cliff Beverage Works issued a voluntary recall of its Beverage Base Lemonade, which was sold in three and five-gallon containers. The five-gallon products have a Best By date of January 1, 2026, while the three-gallon ones have a Best By date of December 12, 2025.
The recall involves 8,847 units of the lemonade, as noted by the Food and Drug Administration (FDA). Affected products were sold in eight states: Arkansas, California, Colorado, Kentucky, Missouri, New Mexico, Oklahoma, and Texas.
The product was recalled due to an undeclared presence of a synthetic food dye, Yellow 5, in the drink.
On February 25, the recall on the Beverage Base Lemonade was classified as a Class II recall. This classification means the recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA.
Various animal studies have linked Yellow 5, also known as tartrazine, to cancer. As shown in a 2024 study published in the journal Science, the skin and muscle tissues of live mice turned transparent when tartrazine was applied to them.
A 2015 study published by Anticancer Research also found that Yellow 5 caused damage to human white blood cells after three hours of exposure to the synthetic dye. Ultimately, researchers found that being exposed to Yellow 5 over time can make tumor growth and cancer more likely.
The classification of the recall, due to Yellow 5, comes after the FDA banned the dye known as Red 3 from the nation's food supply. Red 3 has often been used in candies, cough syrup, baked goods, and frozen treats.
The agency said it was taking the action because studies found that the dye, also known as erythrosine, caused cancer in lab rats. A federal statute requires the FDA to ban any additive found to cause cancer in animals, though officials stressed that the way Red 3 leads to cancer in rats doesn't happen in people.
Nine dyes, including Yellow 5, have been allowed in U.S. food. The other common color additives in food are Blue 1, Blue 2, Green 3, Red 40, and Yellow 6. Two permitted colors are used more rarely: Citrus Red 2 and Orange B.
There have already been a slew of food recalls in 2025. Earlier this month, Tri-Union Seafoods announced a voluntary recall of select canned tuna products sold under the Genova, Van Camp's, H-E-B, and Trader Joe's brands. These products were distributed nationwide at retailers such as Walmart, Trader Joe's, Costco, Kroger, and Publix.
Tri-Union Seafoods initiated the recall after its supplier discovered a manufacturing defect in the tuna cans' 'easy open' lids. The defect could 'compromise the integrity of the product seal (especially over time), causing it to leak, or worse, be contaminated with clostridium botulinum,' a bacteria that causes foodborne botulism and can be fatal.
Also in February, the FDA issued a report about 60 different baked goods from FGF, LLC, which were distributed in grocery stores throughout the U.S. The recall, which was completed in January, affected a total of 2,0176,614 cases of the different baked goods, due to the 'potential for contamination with listeria,' a bacteria that can contaminate many foods and cause infections.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

Yahoo

timean hour ago

  • Yahoo

Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company

UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base. The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa. " This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica's TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients. ," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica signs agreement with fifth Tier-1 US biopharma company SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio

Argenx presents new Efgartigimod data at EULAR 2025
Argenx presents new Efgartigimod data at EULAR 2025

Business Insider

time5 hours ago

  • Business Insider

Argenx presents new Efgartigimod data at EULAR 2025

argenx (ARGX) SE 'announced the presentation of positive results from Phase 2 studies evaluating VYVGART in Sjogren's disease and idiopathic inflammatory myopathies at the European Congress of Rheumatology, EULAR 2025, from June 11 – 14 in Barcelona, Spain. argenx also announced that the FDA has granted efgartigimod Fast Track designation for the treatment of primary Sjogren's disease.' Confident Investing Starts Here: Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory

Yahoo

time6 hours ago

  • Yahoo

ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory

We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store